| Not Yet Recruiting | Pressurized Intraperitoneal Aerosolized Chemotherapy With Mitomycin for the Treatment of Unresectable Appendix NCT07271355 | City of Hope Medical Center | Phase 3 |
| Withdrawn | STIL101 for Injection for the Treatment of Locally Advanced, Metastatic or Unresectable Pancreatic Cancer, Col NCT06626256 | City of Hope Medical Center | Phase 1 |
| Recruiting | Intraperitoneal Oxaliplatin and Fluorouracil for the Treatment of Patients With Peritoneal Metastases From Col NCT06269978 | Arjun Mittra | Phase 1 |
| Recruiting | A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours NCT06147037 | AstraZeneca | Phase 1 |
| Recruiting | Local Liver Treatment for Multi-organ Colorectal Cancer Metastases NCT06449937 | Anhui Provincial Hospital | N/A |
| Recruiting | Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected NCT06265285 | Mayo Clinic | Phase 2 |
| Recruiting | Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform NCT06349642 | Mayo Clinic | — |
| Recruiting | Testing the Addition of an Anti-Cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment (Capecitabine) for NCT05803382 | National Cancer Institute (NCI) | Phase 1 |
| Unknown | Clinical Study Evaluating the Anticancer Effect of Pentoxiphylline in Patients With Metastatic Colorectal Canc NCT06115174 | Tanta University | Phase 4 |
| Recruiting | Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Al NCT05863195 | ECOG-ACRIN Cancer Research Group | Phase 3 |
| Recruiting | CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Pati NCT05733000 | Northwestern University | Phase 2 |
| Recruiting | First-in-human Phase I Study to Evaluate Safety, Tolerability and Antineoplastic Activity of OATD-02 in Patien NCT05759923 | Molecure S.A. | Phase 1 |
| Active Not Recruiting | BXQ-350 in Newly Diagnosed Metastatic Colorectal Carcinoma NCT05322590 | Bexion Pharmaceuticals, Inc. | Phase 1 / Phase 2 |
| Completed | A Vaccine (PolyPEPI1018 Vaccine) and TAS-102 for the Treatment of Metastatic Colorectal Cancer NCT05130060 | Mayo Clinic | Phase 1 |
| Completed | Pixatimod (PG545) Plus Nivolumab in PD-1 Relapsed/Refractory Metastatic Melanoma and NSCLC and With Nivolumab NCT05061017 | Diwakar Davar | Phase 2 |
| Active Not Recruiting | Testing the Addition of an Anticancer Drug, BAY 1895344, to the Usual Chemotherapy With FOLFIRI in Advanced or NCT04535401 | National Cancer Institute (NCI) | Phase 1 |
| Recruiting | Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tu NCT04704661 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Riluzole in Combination With mFOLFOX6 and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer NCT04761614 | Ning Jin | Phase 1 |
| Recruiting | Cryoablation Combined With Stereotactic Body Radiation Therapy for the Treatment of Painful Bone Metastases, t NCT04693377 | M.D. Anderson Cancer Center | N/A |
| Active Not Recruiting | LY3214996 and Cetuximab Alone or in Combination With Abemaciclib for the Treatment of Unresectable or Metastat NCT04616183 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Active Not Recruiting | SX-682 and Nivolumab for the Treatment of RAS-Mutated, MSS Unresectable or Metastatic Colorectal Cancer, the S NCT04599140 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Recruiting | BRAF Inhibitor Encorafenib And Cetuximab Real Life Investigation of Next Generation CRC Treatment NCT04673955 | Pierre Fabre Pharma GmbH | — |
| Completed | Dasatinib for the Prevention of Oxaliplatin-Induced Neuropathy in Patients With Metastatic Gastrointestinal Ca NCT04164069 | Anne Noonan | Phase 1 |
| Unknown | Pemigatinib for the Treatment of Metastatic or Unresectable Colorectal Cancer Harboring FGFR Alterations NCT04096417 | Academic and Community Cancer Research United | Phase 2 |
| Recruiting | PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorecta NCT04329494 | City of Hope Medical Center | Phase 1 |
| Recruiting | An Investigational Scan (Intravoxel Incoherent Motion Diffusion Weighted Imaging) for the Evaluation of Colore NCT04796818 | M.D. Anderson Cancer Center | N/A |
| Recruiting | Radiation Therapy for the Treatment of Metastatic Gastrointestinal Cancers NCT04221893 | University of California, San Francisco | N/A |
| Completed | An Imaging Agent (I-124 M5A) in Detecting CEA-Positive Liver Metastases in Patients With Colorectal Cancer NCT03993327 | City of Hope Medical Center | Phase 1 |
| Completed | Regorafenib, Ipilimumab and Nivolumab for the Treatment of Chemotherapy Resistant Microsatellite Stable Metast NCT04362839 | City of Hope Medical Center | Phase 1 |
| Active Not Recruiting | Panitumumab, Regorafenib, or TAS-102, in Treating Patients With Metastatic and/or Unresectable RAS Wild-Type C NCT03992456 | Academic and Community Cancer Research United | Phase 2 |
| Completed | Binimetinib and Palbociclib or TAS-102 in Treating Patients With KRAS and NRAS Mutant Metastatic or Unresectab NCT03981614 | Academic and Community Cancer Research United | Phase 2 |
| Terminated | CD8+ T Cell Therapy and Pembrolizumab in Treating Patients With Metastatic Gastrointestinal Tumors NCT02757391 | M.D. Anderson Cancer Center | Phase 1 |
| Active Not Recruiting | Microwave Ablation or Wedge Resection for the Treatment of Lung, Sarcoma and Colorectal Lesions, ALLUME Study NCT04430725 | M.D. Anderson Cancer Center | — |
| Recruiting | Intravital Microscopy in Human Solid Tumors NCT03823144 | Mayo Clinic | N/A |
| Active Not Recruiting | TAS-102 and Oxaliplatin for the Treatment of Refractory Stage IV Colon Cancer NCT04294264 | Rutgers, The State University of New Jersey | Phase 2 |
| Active Not Recruiting | Liposomal Irinotecan, Fluorouracil, Leucovorin Calcium, and Rucaparib in Treating Patients With Metastatic Pan NCT03337087 | Academic and Community Cancer Research United | Phase 1 / Phase 2 |
| Completed | Trametinib and Trifluridine and Tipiracil Hydrochloride in Treating Patients With Colon or Rectal Cancer That NCT03317119 | City of Hope Medical Center | Phase 1 |
| Completed | Utomilumab, Cetuximab, and Irinotecan Hydrochloride in Treating Patients With Metastatic Colorectal Cancer NCT03290937 | M.D. Anderson Cancer Center | Phase 1 |
| Active Not Recruiting | Durvalumab and Tremelimumab With or Without High or Low-Dose Radiation Therapy in Treating Patients With Metas NCT02888743 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Capecitabine and Bevacizumab With or Without Atezolizumab in Treating Patients With Refractory Metastatic Colo NCT02873195 | Academic and Community Cancer Research United | Phase 2 |
| Terminated | Liver Surgery and Chemotherapy in Treating Patients With Colorectal Cancer With Liver Metastases That Can Be R NCT02738606 | M.D. Anderson Cancer Center | Phase 2 |
| Active Not Recruiting | M6620 and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Rem NCT02595931 | National Cancer Institute (NCI) | Phase 1 |
| Withdrawn | A Study to Estimate Overall Survival in Patients Receiving Best Supportive Care for Treatment-Resistant, Metas NCT03096899 | The Rogosin Institute | — |
| Active Not Recruiting | Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer NCT02298959 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | A Study Of PF-05212384 Plus FOLFIRI Versus Bevacizumab Plus FOLFIRI In Metastatic Colorectal Cancer NCT01937715 | Pfizer | Phase 1 / Phase 2 |